We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

ZEUS SCIENTIFIC

ZEUS Scientific provides high-performing, easy-to-use clinical diagnostic solutions. The company’s products are desig... read more Featured Products: More products

Download Mobile App




State-of-the-Art IFA Automation Solution Improves Laboratory Workflow

By LabMedica International staff writers
Posted on 19 May 2023

Laboratories are focused on improving efficiency, accuracy, and most importantly, productivity. More...

Now, a complete system for indirect fluorescent antibody (IFA) slide processing and digital immunofluorescence imaging allows labs to increase their productivity while leaving them free to focus on more important tasks.

ZEUS Scientific’s (Branchburg, NJ, USA) new dIFine 30 System combines its next-generation digital IFA imaging and interpretation system with its user-friendly and efficient benchtop instrument for IFA slide processing, including cover slipping. The SP30, a fully automated IFA slide processor for the dIFine digital immunofluorescence system, is an easy-to-use and efficient walk-away benchtop instrument. Capable of processing up to 240 samples on 30 IFA slides, including cover slipping, the SP30 IFA slide processor for dIFine is engineered to enhance laboratory workflow and guarantee superior results.

ZEUS dIFine represents the future of IFA imaging and pattern recognition. This FDA-approved, automated digital scanner equipped with intelligent software is designed to acquire, analyze, display, and store digital images of ZEUS HEp-2 IFA slides. ZEUS dIFine rapidly generates positive/negative results and has received FDA clearance to suggest eight common ANA HEp-2 patterns (homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic, ribosomal, and mitochondrial). Additionally, dIFine can quickly locate and identify mitotic cells to aid in pattern identification. The ability to rapidly view and validate all negative samples with a single mouse click saves the user precious time. The built-in pattern atlas serves as a reference and a useful training tool, allowing for side-by-side comparison of images with ZEUS proprietary images aligned with ICAP nomenclature.

Related Links:
ZEUS Scientific 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.